expertise, études et conseils dans des organisations, cabinets ou sociétés fournissant des prestations intellectuelles, des expertises scientifiques, prospectives ou stratégiques*

Coordonnées

22 rue Hermel 75018 PARIS 18E ARRONDISSEMENT

Techniques maîtrisées

Microsoft Word, Microsoft PowerPoint, Microsoft Excel, Basic SQL, Visio Expertise: Business Development, Consulting, International Relations, Communications, Healthcare, Market Access, Specialty Pharmaceuticals, Tech Solutions, Biotech

Compétences

Primary & Secondary Research, Business Development, Consulting, Communications, Strategic Planning, Problem-Solving, Negotiation & Collaboration, Critical Analysis, Strategizing, Pressure-Testing Simulations

Doctorat

Intitulé : Biologie-Santé - Spécialité Recherche Clinique et Santé Publique
1ère inscription en thèse : Novembre 2017 / 5A these 2021
École doctorale : Sciences de la Vie et de la Santé
Sujet : Surmonter les défis qui font face aux thérapies géniques pour les maladies génétiques rares du système nerveux central (SNC): du développement à l'autorisation de mise sur le marché et la commercialisation
Directeur de thèse : Mondher TOUMI
Co-directeur : Clément FRANCOIS
Unité de recherche : CEReSS - Centre d’Etudes et de Recherche sur les Services de Santé et la Qualité de Vie
Intitulé de l'équipe :

Master

Intitulé : MSc International Relations
Septembre 2015 - London School of Economics

Langues vivantes

Arabe : C2 - Courant
Français : C1 - Avancé
Anglais : Maternel

Production scientifique

  • Heterogeneous Recommendations for Oncology Products Among Different HTA Systems: A Comparative Assessment.
    Regulatory and Economic Aspects in Oncology Recent Results in Cancer Research 2019
    Jaroslawski Szymon, Hanna Eve, Dabbous Monique, Chachoua Lylia, Toumi Mondher.
    https://link.springer.com/chapter/10.1007/978-3-030-01207-6_4
  • President Trump's prescription to reduce drug prices: from the campaign trail to American Patients First.
    Journal of Market Access and Health Policy 2019
    Monique Dabbous, Clement Francois, Lylia Chachoua, Mondher Toumi
    https://www.tandfonline.com/doi/full/10.1080/20016689.2019.1579597
  • Why American Patients First” is likely to raise drug prices outside of the United States.
    Journal of Market Access and Health Policy 2019
    Monique Dabbous, Cyprien Milea, Steven Simoens, Clement Francois, Claude Dussart, Lylia Chachoua, Borissov Borislav, Mondher Toumi
    https://www.tandfonline.com/doi/full/10.1080/20016689.2019.1650596
  • Managed Entry Agreements: Policy Analysis From the European Perspective
    Value in Health 2020
    Dabbous M., Chachoua L., Caban A., Toumi M
    https://www.valueinhealthjournal.com/article/S1098-3015(20)30041-3/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301520300413%3Fshowall%3Dtrue
  • Joint Collaborations and future perspectives for gene therapies
    Cell & Gene Therapy Insights 2020
    Dabbous M., Borissov B., Dussart C., Toumi M., Hanna E
    https://www.insights.bio/cell-and-gene-therapy-insights/journal/article/1720/Joint-collaborations-and-future-perspectives-for-gene-therapies
  • Health Technology Assessment of Gene Therapies in Europe and the USA: Analysis and Future Considerations
    Cell & Gene Therapy Insights 2019
    Qui T., Hanna E., Dabbous M., Borislav B., Toumi M.
    https://insights.bio/cell-and-gene-therapy-insights/journal/article/115/Health-Technology-Assessment-of-Gene-Therapies-in-Europe-and-the-USA-Analysis-and-Future-Considerations
  • Regenerative Medicine Regulatory Policies: a Systematic Review and International Comparison
    Health Policy 2020
    Qiu T., Hanna E., Dabbous M., Borislav B., & Toumi M.
    https://www.sciencedirect.com/science/article/abs/pii/S0168851020301032?via%3Dihub
  • The diversity in regenerative medicines regulations in Europe, USA and Japan
    Cell & Gene Therapy Insights 2019
    Qiu T., Dabbous M., Chachoua L., Dussart C., and Toumi, M
    https://insights.bio/cell-and-gene-therapy-insights/journal/article/117/The-diversity-in-regenerative-medicines-regulations-in-Europe-USA-and-Japan
  • Amortization of Gene Replacement Therapies: A Health Policy Analysis Exploring a Mechanism for Mitigating Budget Impact of High-Cost Treatments
    Health Policy 2021
    Monique Dabbous, Mondher Toumi, Steven Simoens, Juergen Wasem, , Gauri Saal, Yitong Wang, José Luis Huerta Osuna,Clément François, Lieven Annemans, Johann-Matthias Graf von der Schulenburg, Oriol Sola-Morales, Daniel Malone,Louis P. Garrison
    https://doi.org/10.1016/j.healthpol.2021.11.005
  • TRUMP’S PLANS TO REDUCE DRUG PRICES- FROM THE CAMPAIGN TRAIL TO AMERICAN PATIENTS FIRST
    ISPOR & Value in Health 2018
    Dabbous M., Rémuzat C., Toumi M.
    https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-europe-2018/trumps-plans-to-reduce-drug-prices-from-the-campaign-trail-to-american-patients-first
  • COULD THE US ADMINISTRATION IMPOSE DRUG PRICE RAISES IN THE EUROPEAN UNION (EU)?
    ISPOR & Value in Health 2018
    Dabbous M., Rémuzat C., Dussart C., Toumi M.
    https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-europe-2018/could-the-us-administration-impose-drug-price-raises-in-the-european-union-eu-
  • DOES DISEASE PREVALENCE HAVE AN IMPACT ON PRICE OF ORPHAN DRUGS IN EUROPE?
    ISPOR & Value in Health 2018
    Chachoua L., Hanna E., Achour L., Dabbous M., Toumi M.
    https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-europe-2018/does-disease-prevalence-have-an-impact-on-price-of-orphan-drugs-in-europe-
  • ASSESSMENT OF HTA AND PRICE HETEROGENEITY OF ONCOLOGY PRODUCTS- A COMPARISON BETWEEN FRANCE AND GERMANY
    ISPOR & Value in Health 2018
    Dabbous M., Hanna E., Chachoua L., Dussart C., Toumi M.
    https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-asia-pacific-2018/assessment-of-hta-and-price-heterogeneity-of-oncology-products-a-comparison-between-france-and-germany
  • INTERNATIONAL COMPARISON OF HTA DECISIONS FOR ONCOLOGY PRODUCTS
    ISPOR & Value in Health 2018
    Dabbous M., Achour L., Chachoua L., Hanna E., Toumi M.
    https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-asia-pacific-2018/international-comparison-of-hta-decisions-for-oncology-products
  • HOW DOES G-BA DECISION IMPACT ONCOLOGY DRUG PRICES IN GERMANY?
    ISPOR & Value in Health 2018
    Chachoua L., Dabbous M., Achour L., Hanna E., Toumi M., Borissov BN.
    https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-asia-pacific-2018/how-does-g-ba-decision-impact-oncology-drug-prices-in-germany-
  • EUROPEAN COLLABORATION FOR INNOVATIVE HIGH COST MEDICINES
    ISPOR & Value in Health 2018
    Achour L., Chachoua L., Dabbous M., Hanna E., Toumi M.
    https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-asia-pacific-2018/european-collaboration-for-innovative-high-cost-medicines
  • ARE ORPHAN DRUG PRICES FAIR?
    ISPOR & Value in Health 2018
    Hanna E., Chachoua L., Dabbous M., Achour L., Toumi M.
    https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-asia-pacific-2018/are-orphan-drug-prices-fair-
  • DOES DISEASE AREA HAVE AN IMPACT ON ORPHAN DRUG PRICES?
    ISPOR & Value in Health 2018
    Hanna E., Chachoua L., Dabbous M., Dussart C., Toumi M.
    https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-asia-pacific-2018/does-disease-area-have-an-impact-on-orphan-drug-prices-
  • COMPARISON OF ORPHAN DRUGS PRICES- A EUROPEAN COMPARISON
    ISPOR & Value in Health 2018
    Hanna E., Chachoua L., Achour L., Dabbous M., Toumi M.
    https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-asia-pacific-2018/comparison-of-orphan-drugs-prices-a-european-comparison
  • OVERCOMING MARKET ACCESS AND COMMERCIALIZATION CHALLENGES IN GENE THERAPIES FOR RARE CNS DISEASES- GENE THERAPY CLINICAL TRIALS FOR RARE CNS DISEASES LANDSCAPE
    ISPOR & Value in Health 2019
    Dabbous M., François C., Chachoua L., Hanna E., Toumi M.
    https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3122/97743
  • THE ADDED VALUE OF USE OF PATIENT PREFERENCE STUDIES IN POLICY DECISION-MAKING- A LITERATURE REVIEW
    ISPOR & Value in Health 2019
    Chachoua L., Germain N., Dabbous M., François C., Toumi M.
    https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3118/97221
  • Use of Patient Preference Information in Benefit-Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives
    Frontiers Medicine 2020
    Chachoua L., Dabbous M., Francois C., Dussart C., Aballea S., Toumi M.
    https://www.frontiersin.org/articles/10.3389/fmed.2020.543046/full
  • Chinese guidelines related to novel coronavirus pneumonia
    Journal of Market Access and Health Policy 2020
    Tingting Qiu, Shuyao Liang, Monique Dabbous, Yitong Wang, Ru Han, and Mondher Toumi
    https://www.tandfonline.com/doi/full/10.1080/20016689.2020.1818446